Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices

Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.